Business Wire

Rovensa Group Launches Rovensa Next, a New Global Biosolutions Business Unit to Shape a Sustainable Future for Agriculture

Share

Faced with global challenges due to a growing population and climate change, among others, farmers need a solution to feed the planet through healthy and safe solutions. Today, Rovensa Group, a global leader of agricultural inputs for sustainable agriculture, answers that need with Rovensa Next, a new global business unit dedicated to biosolutions for agriculture that aims to give back to the Earth what the Earth gives to us. Rovensa Next makes its debut this week at Fruit Logistica Berlin (Hall 1.2, Stand B-50), the leading trade fair for the fresh fruit industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005486/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

José Alfredo García, Co-COO Rovensa Next, Javier Calleja, incoming CEO Rovensa Group, Eric van Innis, CEO Rovensa Group and Carlos Ledó, Co-COO Rovensa Next (Photo: Business Wire)

Rovensa Next aggregates ten Rovensa Group companies, creating a holistic platform of innovative biosolutions to shape a sustainable future for agriculture and drive its bio-transformation. With this announcement, Agrichembio, Agrotecnología, Idai Nature, Microquimica, MIP Agro, OGT, Oro Agri, Rodel, SDP, and Tradecorp will become part of the new business unit, combining local technical knowledge, innovation and teams that work alongside farmers and distributors in the field to solve their sustainability challenges, with the global expertise and leadership of Rovensa Group.

Eric van Innis, Rovensa Group CEO, stated: “With this flagship project Rovensa Next, and our holistic platform of biosolutions, we are taking a strategic step forward in our goal to be a reference provider of well-balanced and sustainable solutions for agriculture. Farmers and distributors do not need a singular product or a multi-card generalist; they need specialised advisors to help them create a potent strategy that considers their local environment and challenges. Rovensa Next is our answer to our partners’ needs for sustainable crop management that leads to safe and healthy products with better quality and increased yield.”

Betting on sustainability, innovation, and technical expertise, Rovensa Next unites a global network of 30 R&D laboratories, excellence centres, fields, and greenhouses; 14 production plants; more than 84 partnerships with research centres and universities; 100 R&D and innovation specialists; and a dedicated team of more than 850 field expertsi. All of this allows Rovensa Next to be the pioneer on cutting-edge research to create more effective and environmentally friendly biosolutions that don’t compromise on performance or quality.

Carlos Ledó, Co-Chief Operating Officer of Rovensa Next, commented: “With a rising population and a rapidly changing climate, there is a clear need to transform the agricultural sector. The formation of Rovensa Next, consisting of ten brands with entrepreneurship in their DNA, gives us the right talent, know-how, expertise, and innovation to drive the necessary change in agriculture. The time is now for sustainable transformation.”

José Alfredo García, Co-Chief Operating Officer of Rovensa Next, added:We want to be a trusted partner that helps our customers drive sustainable transformation without compromising on performance and yield output. Our unique value add is our team of field experts that work on the ground with growers to understand their needs and solve their challenges. By uniting all of our local and specialised expertise in various crops and geographical areas into one global portfolio of solutions, we aim to help facilitate, or even kickstart, the bio-transformation for customers, ultimately helping to shape an overall more sustainable future.”

With the new business unit, Rovensa Group anticipates a turnover of more than EUR 1 billion by 2025i. Today’s announcement marks the beginning of the global transition to Rovensa Next followed by local implementation across all countries from July 2023.

For more information, go to www.rovensanext.com

About Rovensa Group

Rovensa Group is a global leader in agricultural solutions for sustainable agriculture. It is a group of companies that develop, manufacture, and commercialise agricultural solutions to help farmers produce safe, healthy and nutritious food for all.

Committed to generating a positive impact through its companies, more than 4,000 employees strive each day to contribute to our mission of feeding the planet. With more than 30 Research and Development (R&D) experimental centres and laboratories across the world, we are leading the change in agriculture through science-led innovation to continuously develop pioneering agricultural inputs to preserve and enhance soil, environmental, and human health. We are providing farmers, spread over 80 countries across the globe, a complementary portfolio of solutions for bionutrition, biocontrol and crop protection to support the transition towards a more well-balanced agriculture, enabling them to grow a larger quantity and higher quality of food with fewer natural resources.

For more information, go to www.rovensa.com

  1. Rovensa Next figures including ten aggregated companies and the Cosmocel acquisition.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:
Rovensa Next
Elisa Lipperheide
Global Communication Manager
elisa.lipperheide@rovensanext.com
m. +34 687 111 148

Chelsey Rodowicz
Ogilvy PR
chelsey.rodowicz@ogilvy.com
m. +34 620 035 403

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye